Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
| Revenue (Most Recent Fiscal Year) | $24.99M |
| Net Income (Most Recent Fiscal Year) | $-117.12M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -77.90% |
| Return on Assets (Trailing 12 Months) | -64.35% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 153.26M |
| Free Float | 146.21M |
| Market Capitalization | $82.30M |
| Average Volume (Last 20 Days) | 1.73M |
| Beta (Past 60 Months) | 1.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |